January kicked off the year with a flurry of notable leadership transitions across the pharmaceutical and biotechnology sectors. Here is a detailed look at the latest hires and departures.

February is the shortest month, but there was still plenty of time for a rush of pharma and biotech hires, including a number of changes at the big pharmas, which may have slipped under your radar ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to ...

The workforce reduction will be complete by July 14. Story June 10 - Recursion Pharmaceuticals: The AI biotech is laying off a fifth of its workforce in connection with a previously announced ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

Curevac wird vom viel größeren Rivalen Biontech übernommen. Der Standort wird weiter eine wichtige Rolle spielen. Davon ist eine Expertin überzeugt.

Virginia–based biotech, Insmed. MBV parent Merck's planned acquisition of Schering-Plough, in Kenilworth, New Jersey, will also significantly bolster the pharma's overall biologics capabilities.

Some of these drugs will never hit the shelf of pharmaceuticals even after countless clinical trials. On the other hand, if a biotech company gets a new drug sanctioned by the FDA and the demand ...

Is the long-awaited cure for cancer right around the corner? While the insidious disease continues to plague millions ...